INHSU 2022 Scientific Program Committee
INHSU 2022’s scientific program committee features some of the leading experts in epidemiology and public health in hepatitis C, other infectious diseases, and the broader health of people who use drugs.
Dr Alison Munro is a Senior Lecturer, Health Sciences, at the University of Dundee.
Andrew has worked locally and nationally in the addictions field since 2005. He is currently Consultant Scientist at Public Health Scotland where he has a lead role for blood-borne viruses and other infections involving people who inject drugs (PWID). At Glasgow Caledonian University, Andrew has a senior role on multiple studies including the Needle Exchange Surveillance Initiative (NESI); a bio-behavioural survey of PWID ongoing since 2008.
Dr Andrew Radley is a Consultant in Public Health Pharmacy, NHS Tayside.
Brian Stephens is an Outreach Nurse Specialist in Hepatitis, NHS Tayside.
Professor Catriona Matheson is a Professor at the University of Stirling. Professor Matheson is also an independent research consultant and a Trustee of the Society for the Study of Addiction and Convenor of the Drugs Research Network Scotland (DRNS), based at University of Stirling. Her research interests are in the delivery of care to people who use drugs through generalist as well as specialist providers.
Dave qualified as a registered nurse in 2005 from the University of Dundee, and subsequently built his clinical career within the fields of infectious diseases and sexual health. After moving into academia in 2017, he joined Glasgow Caledonian University in March 2021, and teaches across the undergraduate and postgraduate nursing programmes, and the Masters of Public Health. He also supervises Masters and PhD students.
Erika is an MD-PhD and specialist in internal, tropical and addiction medicine. From 2012 to 2018 she developed integrated care services at the University Hospital from Lausanne for People who inject drugs. Since 2019 she works in her practice as clinician and project leader of the Hepatitis C microelimination virtual clinic initiative. She is a former board member of INHSU (2017 to 2021).
Erika collaborates as medical trainer for the University of Lausanne and for the UNODC treatmnet program in LMIC.
Research interests: People living with HIV, HCV and other transmissible diseases.
Dr Erica Peters is an Infectious Diseases and General Medicine consultant in the Queen Elizabeth University Hospital, Glasgow. She is the clinical lead for the current HIV outbreak amongst homeless PWIDs in Glasgow. She has experience in setting up prison and addiction based clinics for Hepatitis C since 2009 and as part of her medical inpatient work often manages infections in vulnerable populations. She has advocated for resource and support in setting up a high quality service that has been adapted to the complex needs of this population in an environment that is non-judgmental and easily accessible for patients.
Fiona Marra is Principal Pharmacist and part of the Editorial Board of the University of Liverpool, Drug Interactions websites, where she writes the content. She works clinically in Glasgow where is Lead Clinician for paediatric Infectious Disease for Scotland is lead pharmacist for adult HIV/HCV and currently a principal pharmacist in Public Health Scotland for COVID prescribing.
Professor Foster is the Professor of Hepatology at Queen Mary University of London and a consultant at Barts Health Trust. He trained in Medicine at Oxford and London Universities in the 1980s and completed a PhD in Molecular Biology in 1992. Professor Foster has a long standing interest in the management of chronic viral hepatitis and runs a clinical research program studying the natural history of viral hepatitis, its impact upon patients and their communities and novel therapies for this disease. He supervises a laboratory research program investigating the basic virology of hepatotropic viruses novel replication models for hepatitis C. He is the editor of The Journal of Viral Hepatitis and has published widely in the field of viral liver disease. He is the NHSE clinical lead for hepatitis C.
Dr Hannah Carver is a Lecturer in Substance Use in the Faculty of Social Sciences and Co-Director of the Salvation Army Centre for Addiction Services and Research (SACASR). Dr Carver’s research interests include substance use, vulnerable populations, health inequalities, harm reduction and qualitative methodology. Prior to joining the University of Stirling, Dr Carver completed a PhD at Edinburgh Napier University, where her PhD research looked at substance use communication between looked after young people and their formal carers.
Jan Tait is Lead Clinical Nurse Specialist in Gastroenterology at Ninewells Hospital, Dundee, Scotland. She completed a BSc in Nursing at Queen Margaret’s University, Edinburgh and a MSc in Advanced Nursing Practice at Dundee University. She has provided a nurse-led hepatitis service for the last 20 years.
Jo Neale is Professor of Addictions Qualitative Research based within the National Addiction Centre and working across the Biomedical Research Centre for Mental Health at the Institute of Psychiatry, Psychology & Neuroscience. She is also Conjunct Professor in the Centre for Social Research in Health at the University of New South Wales, Australia. Jo is a social scientist by training and qualified as a social worker in 1989. She subsequently completed an MSc in Women’s Studies and a DPhil in Social Policy and Social Work at the University of York.
Josie Smith is the Senior Epidemiologist – Lead for BBV, STIs, TB and Inequalities at Public Health Wales. Prior to this she was Head of Substance Misuse Programme, Public Health Wales leading development of a range of national harm reduction initiatives and surveillance systems to evidence trends in risk behavior and infectious disease and undertaking research on problematic drug use prevalence and the acute and chronic harms associated with psychoactive drugs both licit and illicit, image and performance enhancing drugs and alcohol.
Magdalena Harris is a sociologist working with qualitative methods in the social science of drug use, health and harm reduction. She works in partnership with community organisations, and through peer research, in the fields of hepatitis C, opioid and crack use, and opioid substitution treatment service delivery. Magdalena is Associate Professor at the London School of Hygiene and Tropical Medicine, Associate Editor for the International Journal of Drug Policy and holds an honorary Inclusion Health Consultant position at University College London Hospital NHS Trust.
Monica Desai is Consultant Epidemiologist and Head of Hepatitis C at UKHSA.
Philip Bruggmann is internal medicine specialist and has worked as head of internal medicine at Arud in Zurich, Switzerland since 2003. An association founded in 1991, Arud runs two outpatient clinics for addiction medicine that provide an interdisciplinary holistic care setting with a full range of hepatitis and HIV care. 2010 he co-founded INSHU and served as its first president.
Philip chairs Swiss Hepatitis, a civil society organization running the Swiss Hepatitis Strategy. He is a Privatdozent and research associate at the Institute of Family Medicine of the University of Zurich.
Dr Saket Priyadarshi is the Associate Medical Director in Greater Glasgow and Clyde alcohol and drug services. He is responsible for the professional leadership of medical staff and clinical governance in Alcohol and Drugs services in the largest health board in Scotland. He is a graduate of the University of Glasgow medical school and qualified as a General Practitioner in 2003. Through working in deprived areas in the west of Scotland, he developed an interest in the management of substance misuse problems.
Dr Stephen Barclay is a Gastroenterologist at Glasgow Royal Infirmary, Scotland. He co-chairs Glasgow’s viral hepatitis Managed Care Network, which delivers over one third of Scotland’s HCV treatments. He has been involved in expanding HCV outreach clinics in addictions centres and community health centres, such that the majority of Glasgow’s HCV care is provided in community settings. He has ongoing involvement in commercial and academic trials in HCV, HBV, and autoimmune liver disease.
Tim is Professor of Public Health Sociology at ISHTM. Tim focuses on the sociology of health using qualitative methods. His work concentrates on the social relations of access to care, especially in relation to drug use, addictions, HIV and hepatitis C. His recent and current qualitative research explores the implementation of harm reduction and health care interventions among people who inject drugs in East Africa, Colombia and Myanmar. He is currently also focused on the development of critical approaches, informed by science and technology studies, to the study of implementation science, including in the fields of COVID-19, hepatitis C and disease control.
Vana Sypsa is Associate Professor of Epidemiology and Medical Statistics in the Medical School of the National and Kapodistrian University of Athens in Greece. Her research interests include the epidemiology and mathematical modeling of hepatitis C, HIV, SARS-CoV-2 and other infectious diseases as well as interventions among people who inject drugs and people living in prisons. She has participated in advisory boards to prepare and implement the national hepatitis C and HIV plans in Greece. She was President of the International Society for Clinical Biostatistics in 2019-2020. She is member of the national scientific committee of experts for COVID-19 in Greece.
Viv is currently Professor of Public Health at the Public Health Institute, Liverpool John Moore University. Prior to this he worked at Public Health England, and he has held academic posts at London School of Hygiene & Tropical Medicine, Imperial College London, and the University of Birmingham. He has over 25 years’ experience of research and public health practice focused on understanding the health harms associated with drug use and the responses to these. His research has focused on the harms associated with the injection of drugs, particularly infections, and preventing drug-related deaths.